In mid-July, Amgen agreed to settle a tying case in which a competitor alleged that the anemia drug producer’s pricing policies effectively tied the purchase of a competitive drug to two others in which it held a monopoly position. Related litigation involving this pricing practice is on-going.
Update: In late September, the Sheet Metal Workers National Health Fund voluntarily dismissed a putative class action against Amgen based on similar tying claims. Portions of the complaint had been thrown out in a mid-August decision.